Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
JNT-517
/
Jnana Therap
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
|
|||||||||
JNT-517
/
Jnana Therap
Trial completion:
First in human clinical study of a novel drug JNT-517 to assess its safety and tolerability in healthy volunteers
(EUDRACT) - Jan 19, 2024
P1
, N=72, Completed,
Sponsor: CTI Clinical Trial and Consulting Services Australia Pty Ltd.
Active, not recruiting --> Completed
|
|||||||||
JNT-517
/
Jnana Therap
Trial completion, Trial initiation date:
First in human clinical study of a novel drug JNT-517 to assess its safety and tolerability, effects of food intake and to compare JNT-517 levels when taken as an oral suspension and tablet formulation.
(EUDRACT) - Sep 2, 2023
P1
, N=12, Completed,
Sponsor: CTI Clinical Trial and Consulting Services Australia Pty Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed | Initiation date: Feb 2000 --> Feb 2023
|
|||||||||
JNT-517
/
Jnana Therap
Trial initiation date:
First in human clinical study of a novel drug JNT-517 to assess its safety and tolerability in healthy volunteers
(EUDRACT) - Sep 2, 2023
P1
, N=72, Active, not recruiting,
Sponsor: CTI Clinical Trial and Consulting Services Australia Pty Ltd.
Active, not recruiting --> Completed | Initiation date: Feb 2000 --> Feb 2023 Initiation date: Oct 2000 --> Oct 2022
||||||||||
JNT-517
/
Jnana Therap
Safety, Tolerability and Proof-Of-Mechanism in Healthy Volunteers for JNT-517, a First-In-Class SLC6A19 Inhibitor for the Treatment of Phenylketonuria
(Ussishkin (ICC)) - Jul 6, 2023 - Abstract #SSIEM2023SSIEM_220;
Initiation date: Oct 2000 --> Oct 2022 JNT-517 is a safe and well-tolerated novel SLC6A19 inhibitor, which effectively increases the excretion of neutral amino acids including Phe in urine and warrants investigation as a potential therapeutic candidate for PKU.
|
|||||||||
JNT-517
/
Jnana Therap
New P1 trial:
First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria
(clinicaltrials.gov) - Mar 23, 2023
P1
, N=112, Recruiting,
Sponsor: Jnana Therapeutics